Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Assets (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Current Assets for 4 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 180.7% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 180.7% year-over-year, with the annual reading at $7.6 million for FY2025, 180.7% up from the prior year.
  • Current Assets for Q4 2025 was $7.6 million at bioAffinity Technologies, down from $8.6 million in the prior quarter.
  • The five-year high for Current Assets was $14.1 million in Q3 2022, with the low at $1.7 million in Q2 2025.
  • Average Current Assets over 4 years is $6.2 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Current Assets plummeted 69.05% in 2024, then soared 237.9% in 2025.
  • Over 4 years, Current Assets stood at $12.0 million in 2022, then crashed by 66.79% to $4.0 million in 2023, then plummeted by 32.16% to $2.7 million in 2024, then soared by 180.7% to $7.6 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $7.6 million, $8.6 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.